Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median Overall Survival (OS) in Patients with BRAF-Mutant Melanoma in Phase 3 COLUMBUS Trial
Go back to Encorafenib and Binimetinib Combination Treatment Demonstrates 33.6 Month Median Overall Survival (OS) in Patients with BRAF-Mutant Melanoma in Phase 3 COLUMBUS Trial| Array Biopharma, Inc. (NASDAQ: ARRY) | Delayed: 7.77 +0.32 (4.30%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.45 | 52 Week High | $7.27 | |||
| Open | $7.56 | 52 Week Low | $2.39 | |||
| Day High | $8.05 | P/E | N/A | |||
| Day Low | $7.52 | EPS | $-0.61 | |||
| Volume | 6,075,665 | |||||
